Blocking cells’ movement to stop spread of cancer
Scientists discovered that cells can change into an invasive, liquid-like state to readily navigate the narrow channels in our body. …
Scientists discovered that cells can change into an invasive, liquid-like state to readily navigate the narrow channels in our body. …
The results of their study are published in the journal Cancer Cell. The research team led by Sloan-Kettering researchers studied a tumor suppressor called Merlin. …
Principal investigators and co-leaders of Tulane’s Circadian Cancer Biology Group, Steven Hill and David Blask, along with team members Robert Dauchy and Shulin Xiang, investigated the role of melatonin on the effectiveness of tamoxifen in combating human breast cancer cells implanted in rats. “In the first phase of the study, we kept animals in a daily light/dark cycle of 12 hours of light followed by 12 hours of total darkness (melatonin is elevated during the dark phase) for several weeks,” says Hill…
The current results are based on a genome-wide association study, a type of study in which researchers examine numerous genetic variants to see if any of them are associated with a certain type of complication, which could sometimes emerge years after treatment was completed. “Our findings, which were replicated in two additional patient groups, represent a significant step towards developing personalized treatment plans for prostate cancer patients,” said Barry S. …
The study also suggested that traditional methods of measuring the severity and possible spread of the cancer together with molecular techniques might, with further research, help to create personalized, cost-effective treatment regimens for prostate cancer patients who undergo the surgical procedure. The findings apply to men whose cancer has not spread beyond the prostate, and the results are comparable to the well-established and more invasive open surgery to remove the entire diseased prostate and some surrounding tissue. The research study is published this month online in European Urology, the official journal of the European Association of Urology. “Until our analysis, there was little available information on the long-term oncologic outcomes for patients who undergo robot-assisted radical prostatectomy, or RARP,” says Mireya Diaz, Ph.D., Director of Biostatistics at the Henry Ford’s Vattikuti Urology Institute (VUI) and lead author of the study…
PD-L1 is a protein that plays an important role in suppressing immune response, and in cancer, it may allow tumors to evade immune attack. …
Patients who feel anxious and uneasy with their doctor may be impacted the most. “Anxiously attached patients may experience and report more physical and emotional problems when the relationship with their physician is perceived as less trusting,” said Chris Hinnen, Ph.D., lead author and clinical psychologist at Slotervaart Hospital in Amsterdam, The Netherlands. The researchers acknowledge that the issue of trust between patients and their doctors can be complicated, but observe that it’s important to understand fears of rejection and abandonment that often exist in anxiously attached patients. Hinnen and his colleagues analyzed questionnaire responses from 119 participants with breast, cervical, intestinal or prostate cancers at 3, 9 and 15 months after their diagnosis. …
Despite the commercial availability of electric power morcellators for 2 decades, accurate estimates of the prevalence of malignancy at the time of electric power morcellation (in this study referred to as morcellation) have been lacking, according to background information in the article. Jason D. Wright, M.D., of the Columbia University College of Physicians and Surgeons, New York, and colleagues used a large insurance database to investigate the prevalence of underlying cancer in women who underwent uterine morcellation. …
That experimental capability was developed through a long-term collaboration, focused on clinical cell processing and purification, between researchers based in Munich and Seattle. Since 2009, the groups of Prof…
However, a new Cincinnati Cancer Center (CCC) study, published in the advance online edition of the journal Oncotarget, provides hope that previously studied SapC-DOPS could be used for treatment of brain cancer that has spread. Xiaoyang Qi, PhD, member of the CCC, associate director and associate professor in the division of hematology oncology at the University of Cincinnati (UC) College of Medicine and a member of the UC Cancer and Neuroscience Institutes and the Brain Tumor Center, says this critical data shows promise for finding treatment for one of the deadliest cancers…